Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv44
  2. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027v43
  3. 2 versions Re-verified since May 29, 2025, no change to tracked fieldsv41-v42
  4. Start date: May 2006 to May 15, 2006v40
  5. Re-verified, no change to tracked fieldsv39
Show 37 earlier versionsHide 37 earlier versions
  1. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v38
  2. Re-verified, no change to tracked fieldsv37
  3. Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v36
  4. 2 versions Re-verified since Jun 1, 2023, no change to tracked fieldsv34-v35
  5. Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023v33
  6. Primary and study completion dates: Dec 1, 2022 to Dec 31, 2022v32
  7. Re-verified, no change to tracked fieldsv31
  8. Primary completion date: Dec 1, 2021 to Dec 1, 2022v30
  9. Primary completion date: Dec 1, 2020 to Dec 1, 2021
    • Study completion date: Dec 1, 2021 to Dec 1, 2022
    v29
  10. Primary completion date: Dec 31, 2019 to Dec 1, 2020
    • Study completion date: Dec 31, 2019 to Dec 1, 2021
    v28
  11. Re-verified, no change to tracked fieldsv27
  12. Primary and study completion dates: May 2019 to Dec 31, 2019v26
  13. 4 versions Re-verified since Sep 29, 2017, no change to tracked fieldsv22-v25
  14. Primary completion date: Dec 2018 to May 2019
    • Study completion date: May 2019
    v21
  15. Primary completion date: Dec 2017 to Dec 2018v20
  16. Primary completion date: Dec 2015 to Dec 2017
    • Study completion date: Dec 2015 to not stated
    v19
  17. Primary and study completion dates: Dec 2014 to Dec 2015
    • Study site revised
    v18
  18. Re-verified, no change to tracked fieldsv17
  19. Primary and study completion dates: Dec 2012 to Dec 2014v16
  20. Re-verified, no change to tracked fieldsv15
  21. Primary completion date: Dec 2011 to Dec 2012v14
  22. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v13
  23. Study site revisedv12
  24. Enrollment target: 42 to 64v11
  25. Eligibility criteria shortened, about 11 words
    • Study description expanded, about 34 words
    v10
  26. Re-verified, no change to tracked fieldsv9
  27. Trial status: Active, Not Recruiting to Recruitingv8 Show 5 more changesShow less
    • Primary completion date: Dec 2008 to Dec 2011
    • Primary endpoint revised
    • Study completion date: Dec 2012
    • Study description shortened, about 34 words
    • Site details revised
  28. Primary completion date: May 2008 to Dec 2008v7
  29. Eligibility criteria expanded, about 11 words
    • Primary endpoint revised
    • Study description shortened, about 1 word
    v6
  30. Primary endpoint revisedv5 Show 6 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 36 to 42
    • Interventions: LHRH agonist (Drug), Radical Prostatectomy (Procedure), Sunitinib Malate (Drug) to LHRH Agonist (Drug), Radical Prostatectomy (Procedure), Sunitinib Malate (Drug)
    • Secondary endpoints shortened, about 53 words
    • Study description shortened, about 12 words
    • Site details revised
  31. Primary endpoints: 2 to 1v4 Show 7 more changesShow less
    • Primary completion date: May 2008
    • Interventions: LHRH agonist (Drug), Sunitinib Malate (SU011248) (Drug) to LHRH agonist (Drug), Radical Prostatectomy (Procedure), Sunitinib Malate (Drug)
    • Eligibility criteria expanded, about 169 words
    • Secondary endpoints expanded, about 53 words
    • Study description expanded, about 787 words
    • Site contact updated
    • Study arms: 0 to 1
  32. Interventions: LHRH agonist (Drug), Sunitinib Malate (Drug) to LHRH agonist (Drug), Sunitinib Malate (SU011248) (Drug)
    • Study site revised
    • Collaborators expanded, about 1 word
    v3
  33. Study completion date: May 2006 to not stated
    • Interventions: LHRH agonist and sunitinib malate (Drug) to LHRH agonist (Drug), Sunitinib Malate (Drug)
    • Study title expanded, about 6 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.
Trial Details
NCT Number NCT00329043
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Pfizer
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov